RU96107794A - TRIARILETHYLENE DERIVATIVES FOR USE IN THERAPY - Google Patents
TRIARILETHYLENE DERIVATIVES FOR USE IN THERAPYInfo
- Publication number
- RU96107794A RU96107794A RU96107794/04A RU96107794A RU96107794A RU 96107794 A RU96107794 A RU 96107794A RU 96107794/04 A RU96107794/04 A RU 96107794/04A RU 96107794 A RU96107794 A RU 96107794A RU 96107794 A RU96107794 A RU 96107794A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- compound according
- denotes
- compound
- pharmaceutical composition
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 35
- 150000003839 salts Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 239000003937 drug carrier Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 206010003210 Arteriosclerosis Diseases 0.000 claims 8
- 201000001320 atherosclerosis Diseases 0.000 claims 8
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- -1 4-diethylaminobutoxy Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- UTYMHSHRSOOSEY-BYYHNAKLSA-N 4-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylbutan-1-amine Chemical group C1=CC(OCCCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 UTYMHSHRSOOSEY-BYYHNAKLSA-N 0.000 claims 1
- XWMIYYSYKYTDTE-ZQHSETAFSA-N 5-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylpentan-1-amine Chemical group C1=CC(OCCCCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 XWMIYYSYKYTDTE-ZQHSETAFSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Claims (1)
где A обозначает радикал формул
где R и R1 каждый, независимо, обозначают водород или C1 - C4-алкил;
G обозначает HN, H3CN, CH2 или О;
n обозначает целое число от 4 до 12;
R2 обозначает водород, C1 - C4-алкил, C1 - C4-алкокси, галоген или гидрокси;
R3 обозначает водород, C1 - C4-алкил, C1 - C4-алкокси, галоген, гидрокси или -Y(CH2)pA1, в которой A1 обозначает радикал формулы
где R4 и R5 каждый, независимо, обозначают водород или C1 - C4-алкил;
G1 обозначает HN, H3CN, CH2 или О;
p обозначает целое число от 4 до 12;
x обозначает хлор или бром;
Y обозначает О или NH,
или его фармацевтически приемлемая соль.1. The compound of the formula
where A denotes the radical of the formulas
where R and R 1 each, independently, represent hydrogen or C 1 - C 4 -alkyl;
G is HN, H 3 CN, CH 2 or O;
n represents an integer from 4 to 12;
R 2 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogen or hydroxy;
R 3 denotes hydrogen, C 1 - C 4 -alkyl, C 1 - C 4 -alkoxy, halogen, hydroxy or -Y (CH 2 ) p A 1 in which A 1 denotes a radical of the formula
where R 4 and R 5 each, independently, represent hydrogen or C 1 - C 4 -alkyl;
G 1 denotes HN, H 3 CN, CH 2 or O;
p denotes an integer from 4 to 12;
x denotes chlorine or bromine;
Y is O or NH,
or its pharmaceutically acceptable salt.
где R и R1 обозначают этил.4. The compound according to claim 3, where A denotes a radical of the formula
where R and R 1 denote ethyl.
где A обозначает радикал формулы
где R и R1 каждый, независимо, обозначают водород или C1 - C4-алкил;
G обозначает HN, H3CN, CH2 или 0;
n обозначает целое число от 4 до 12;
R2 обозначает водород, C1 - C4-алкил, C1 - C4-алкокси, галоген или гидрокси,
где R4 и R5 каждый, независимо, обозначают водород или C1 - C4-алкил;
G1 обозначает HN, H3CN, CH2 или O;
p обозначает целое число от 4 до 12;
X обозначает хлор или бром;
Y обозначает O или NH,
или его фармацевтически приемлемая соль.8. The compound of the formula
where A denotes a radical of the formula
where R and R 1 each, independently, represent hydrogen or C 1 - C 4 -alkyl;
G is HN, H 3 CN, CH 2 or 0;
n represents an integer from 4 to 12;
R 2 denotes hydrogen, C 1 - C 4 -alkyl, C 1 - C 4 -alkoxy, halogen or hydroxy,
where R 4 and R 5 each, independently, represent hydrogen or C 1 - C 4 -alkyl;
G 1 denotes HN, H 3 CN, CH 2 or O;
p denotes an integer from 4 to 12;
X is chlorine or bromine;
Y is O or NH,
or its pharmaceutically acceptable salt.
где R и R1 обозначают этил.11. The compound of claim 10, where A denotes a radical of the formula
where R and R 1 denote ethyl.
15. Соединение по п.1 или его фармацевтически приемлемая соль, используемое, необязательно в сочетании с фармацевтически приемлемым носителем, при получении фармацевтической композиции для лечения болезненного состояния, вызванного опухолью.14. The compound according to claim 8, which is (Z) -1- [4- (4-diethylaminobutoxy) phenyl-1- (4-hydroxy) phenyl-2-phenyl-2-chloroethylene
15. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, optionally used in combination with a pharmaceutically acceptable carrier, in the preparation of a pharmaceutical composition for treating a disease state caused by a tumor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/126,614 | 1993-09-24 | ||
US08/259,797 | 1994-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU96107794A true RU96107794A (en) | 1998-07-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95122775A (en) | METHOD FOR REDUCING BONE TISSUE LOSS, METHOD FOR TREATING OSTEOPOROSIS AND CONNECTION | |
CA2405796A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
JP2003520195A5 (en) | ||
RU2002106503A (en) | METHOD FOR TREATING DISEASES MEDIATED BY OPIOID RECEPTORS | |
RU96115142A (en) | Derivatives of 5- (2-imidazolinilamino) benzimidazole, their production and use as agonists of alpha-2 adrenoceptors | |
RU97108069A (en) | Compounds possessing activity in relation to the calcium receptor | |
RU2000102359A (en) | PHARMACEUTICAL COMPOSITION HAVING AN IMPROVED ANTI-CANCER ACTION AND / OR REDUCED SIDE EFFECTS CONTAINING ANTI-CANCER AGENT AND HYDROXAMIC DERIVATIVE DERIVATIVE | |
RU2003101319A (en) | PHARMACEUTICAL COMPOSITION HAVING AN IMPROVED ANTITUMOR ACTION AND / OR REDUCED SIDE EFFECTS CONTAINING AN ANTITUMOR AGENT AND A DERIVATIVE HYDROGEN | |
RU2000111513A (en) | STYRESULPHONIC AGENTS AGAINST CANCER | |
RU94022743A (en) | Amido and carbamido derivatives having antihypercholesteric activity, preparation thereof, and therapeutic use thereof | |
RU95117068A (en) | ANTIHYPERTRIGLICYRIDEMIC COMPOSITION, METHOD FOR PRODUCING IT, METHOD FOR TREATING OR PREVENTION OF HYPERTRIGLYCERIDEMIA, USE OF COMPOUNDS | |
RU97117350A (en) | INTIMA HYPERTROPHY INHIBITOR, OXINDOL DERIVATIVE APPLICATION FOR THE INIMA HYPERTROPHY INHIBITOR INHIBITOR, A COMPOSITION FOR INHIBITING INTIMA HYPERTROPHY, PREVENTION AND TREATMENT HYPERT | |
RU2000123169A (en) | BENZOTHIADIAZOLES AND THEIR DERIVATIVES | |
IS5588A (en) | Anti-tumor agents | |
RU2002101622A (en) | Naphthoquinone derivatives and their use for the treatment and control of tuberculosis | |
RU98119076A (en) | DERIVATIVES OF 2- (3H) -OXASOLONE AND THEIR APPLICATION AS SOX-2 INHIBITORS | |
RU97115107A (en) | BICYCLIC DERIVATIVES OF ISOTHYOTURES USED IN THERAPY | |
RU95113434A (en) | Dimethylbenzofurans and dimethylbenzopyrans, their use as 5-ht3-antagonists, method of synthesis, pharmaceutical composition | |
RU96103685A (en) | 1,2,5-TIADIAZOLIC DERIVATIVES OF INDOLALALKYL-PYRIDINIL-PYRIMIDINIL-PIPERAZINES, METHOD OF TREATMENT OR PREVENTION OF THE DEVELOPMENT OF VASCULAR HEADACHE AND PHARMACEUTICAL COMPOSITION | |
RU98119949A (en) | Α-ADRENERGIC RECEPTOR ANTAGONISTS | |
RU96107794A (en) | TRIARILETHYLENE DERIVATIVES FOR USE IN THERAPY | |
RU2005138143A (en) | MITYLINDOLES AND METHYLPYRROLOPYRIDINES AS L-1-ADRENERGIC AGONISTS | |
RU2004109817A (en) | AMINOPYRROLEN DERIVATIVES AS ANTI-INFLAMMATORY PRODUCTS | |
RU2000102642A (en) | MEDICAL MEANS AGAINST AloPETIA | |
FI923662A0 (en) | THERAPEUTIC MEDEL. |